Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Latest Information Update: 11 Oct 2021
At a glance
- Drugs Hydromethylthionine mesylate (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors TauRx Therapeutics
- 26 Nov 2019 Results of pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine, using blood concentration data from 1,162 of 1,686 patients who had participated in either of two previously completed Phase 3 trials (TRx-237-015 and TRx-237-005) presented in a TauRx Therapeutics media release.
- 26 Nov 2019 According to a TauRx Therapeutics media release, results from 1,162 patients who had participated in either of two previously completed Phase 3 trials that assessed the pharmacological activity were published in Journal of Alzheimers Disease
- 26 Nov 2019 Results of pharmacokinetic analyses (n=1162) published in the Media Release